New York, USA, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Knee Osteoarthritis Market to Witness Upsurge in Growth, Assesses DelveInsight | Key Companies To Look Out - Techfields, Centrexion, Biosplice, Ampio, Paradigm, Grünenthal, Naturecell, MiMedx, TissueTech, Organogenesis
The dynamics of the knee osteoarthritis market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, incremental healthcare spending across the world, and also expected launch of emerging therapies during the forecasted period of 2023–2032.
DelveInsight’s Knee Osteoarthritis Market Insights report includes a comprehensive understanding of current treatment practices, knee osteoarthritis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Knee Osteoarthritis Market Report
- As per DelveInsight’s analysis, the knee osteoarthritis market was ~USD 14 billion in 2021 and it is anticipated to grow at a significant CAGR by 2032.
- As per the DelveInsight estimates, the prevalent population of symptomatic knee osteoarthritis in the seven major markets was found to be ~47 million in 2021. In 2021, the highest prevalent cases of the disease were observed in the United States.
- Leading knee osteoarthritis companies such as Bioventus LLC, Akan Biosciences, LLC, Genascence Corporation, Immunis, Inc., Novartis, Biosplice Therapeutics, Sorrento Therapeutics, Inc., Novartis, Celltex Therapeutics Corporation, MiMedx Group, Inc., Rho, Inc., Techfields Pharma Co. Ltd, Eli Lilly and Company, Nature Cell Co. Ltd., Novo Nordisk A/S, Flexion Therapeutics, Inc., Grünenthal GmbH, Tissue Tech Inc., Kolon TissueGene, Inc., Saol Therapeutics Inc, Centrexion Therapeutics, Taiwan Liposome Company, MiMedx, Ampio Pharmaceuticals, ReNu, Medipost, and others are developing novel knee osteoarthritis drugs that can be available in the knee osteoarthritis market in the coming years.
- Some of the key therapies for knee osteoarthritis treatment include PTP-001, StroMel, GNSC-001, IMM01-STEM, RHH646, Lorecivivint, Resiniferatoxin, DFV890, Celltex- AdMSCs, Micronized DHACM, X0002, Retatrutide, JointStem, Semaglutide, FX201, RTX-GRT7039, TTAX03, TG-C, SL-1002, CNTX-4975, TLC599, Amniofix, Ampion, Organogenesis, Cartistem, and others.
Discover which therapies are expected to grab the major knee osteoarthritis market share @ Knee Osteoarthritis Market Report
Knee Osteoarthritis Overview
Knee osteoarthritis is a prevalent and debilitating condition that affects millions of people worldwide. It is a type of arthritis characterized by the gradual deterioration of the cartilage in the knee joint. The primary causes of knee osteoarthritis are multifactorial and can involve a combination of genetic, lifestyle, and environmental factors. Age is a significant risk factor, as the cartilage naturally wears down over time.
The knee osteoarthritis symptoms typically develop gradually and worsen over time. The most common signs include persistent knee pain, especially during or after physical activity, as well as stiffness and reduced flexibility in the joint. Swelling and tenderness around the knee are also common. As the condition progresses, individuals may experience a decreased range of motion, difficulty in walking or climbing stairs, and a sensation of grating or grinding within the knee joint. Diagnosing knee osteoarthritis involves a combination of medical history assessment, physical examination, and imaging tests. The doctor will inquire about the patient’s knee osteoarthritis symptoms and risk factors while examining the knee for signs of inflammation, tenderness, or deformity.
Knee Osteoarthritis Epidemiology Segmentation
The knee osteoarthritis epidemiology section provides insights into the historical and current knee osteoarthritis patient pool and forecasted trends for the seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
The knee osteoarthritis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Knee Osteoarthritis Prevalent Population
- Knee Osteoarthritis Gender-specific Prevalence
- Knee Osteoarthritis Severity-specific Prevalence
- Knee Osteoarthritis Age-specific Prevalence
Download the report to understand which factors are driving knee osteoarthritis epidemiology trends @ Knee Osteoarthritis Epidemiological Insights
Knee Osteoarthritis Treatment Market
Knee osteoarthritis treatment aims to alleviate pain, improve joint function, and enhance overall quality of life for individuals affected by this degenerative joint condition. The knee osteoarthritis treatment approach typically involves a combination of non-pharmacological and pharmacological interventions. Non-pharmacological methods include exercise programs designed to strengthen the muscles around the knee, physical therapy, and weight management to reduce stress on the joint. Assistive devices like braces or canes can also provide support and aid mobility. Additionally, lifestyle modifications such as adopting a healthy diet rich in anti-inflammatory foods and avoiding excessive activities that strain the knee are encouraged.
Pharmacological treatments often include over-the-counter pain relievers, such as acetaminophen or nonsteroidal anti-inflammatory drugs (NSAIDs), to manage pain and inflammation. In more severe cases, prescription medications like corticosteroids or hyaluronic acid injections may be used to provide relief and reduce joint swelling. For individuals who do not respond well to conservative treatments, surgical options like arthroscopy, osteotomy, or joint replacement may be considered to repair or replace damaged tissue.
The best course of action for knee osteoarthritis treatment depends on the individual's specific condition and the severity of their symptoms. Therefore, it is essential for patients to work closely with healthcare professionals to develop a personalized treatment plan that addresses their unique needs and helps them regain mobility and enjoy an improved quality of life.
To know more about knee osteoarthritis treatment, visit @ Knee Osteoarthritis Treatment Drugs
Key Knee Osteoarthritis Therapies and Companies
- PTP-001: Bioventus LLC
- StroMel: Akan Biosciences, LLC
- GNSC-001: Genascence Corporation
- IMM01-STEM: Immunis, Inc.
- RHH646: Novartis
- Lorecivivint: Biosplice Therapeutics
- Resiniferatoxin: Sorrento Therapeutics, Inc.
- DFV890: Novartis
- Celltex- AdMSCs: Celltex Therapeutics Corporation
- Micronized DHACM: MiMedx Group, Inc./Rho, Inc.
- X0002: Techfields Pharma Co. Ltd
- Retatrutide: Eli Lilly and Company
- JointStem: Nature Cell Co. Ltd.
- Semaglutide: Novo Nordisk A/S
- FX201: Flexion Therapeutics, Inc.
- RTX-GRT7039: Grünenthal GmbH
- TTAX03: Tissue Tech Inc.
- TG-C: Kolon TissueGene, Inc.
- SL-1002: Saol Therapeutics Inc
- CNTX-4975: Centrexion Therapeutics
- TLC599: Taiwan Liposome Company
- Amniofix: MiMedx
- Ampion: Ampio Pharmaceuticals
- Organogenesis: ReNu
- Cartistem: Medipost
Learn more about the FDA-approved drugs for knee osteoarthritis @ Drugs for Knee Osteoarthritis Treatment
Knee Osteoarthritis Market Dynamics
Knee osteoarthritis market dynamics have witnessed significant changes in recent years. With an aging population and an increase in sedentary lifestyles, the prevalence of knee osteoarthritis has surged, driving the demand for effective treatments and therapies. Additionally, advancements in medical research and technology have led to the development of innovative drugs, biologics, and medical devices tailored to manage the condition more efficiently. These innovations, along with the rising awareness of knee osteoarthritis among patients and healthcare professionals, have fueled the growth of the knee osteoarthritis market.
Moreover, regulatory agencies’ efforts to streamline approval processes for new treatments have encouraged pharmaceutical and medical device companies to invest in research and development. This has resulted in a steady influx of novel therapies, creating a highly competitive landscape in the knee osteoarthritis market. As a consequence, pricing strategies, reimbursement policies, and market access have become critical factors for industry players aiming to establish a strong foothold.
Furthermore, patient preferences are shifting towards non-invasive and minimally invasive treatment options, such as physical therapy, viscosupplementation, and orthobiologics. This shift reflects the growing interest in preserving knee function and mobility while managing pain and inflammation. Consequently, companies are aligning their product portfolios to cater to these evolving patient needs.
However, despite the knee osteoarthritis market’s growth potential, challenges persist, including the high cost of novel therapies and the burden of long-term treatment expenses. Additionally, healthcare systems around the world are under pressure to address the socioeconomic impact of knee osteoarthritis, including reduced workforce productivity and increased healthcare expenditure.
| Knee Osteoarthritis Report Metrics | Details |
| Study Period | 2019–2032 |
| Knee Osteoarthritis Report Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
| Knee Osteoarthritis Market Size in 2021 | USD 14 Billion |
| Key Knee Osteoarthritis Companies | Bioventus LLC, Akan Biosciences, LLC, Genascence Corporation, Immunis, Inc., Novartis, Biosplice Therapeutics, Sorrento Therapeutics, Inc., Novartis, Celltex Therapeutics Corporation, MiMedx Group, Inc., Rho, Inc., Techfields Pharma Co. Ltd, Eli Lilly and Company, Nature Cell Co. Ltd., Novo Nordisk A/S, Flexion Therapeutics, Inc., Grünenthal GmbH, Tissue Tech Inc., Kolon TissueGene, Inc., Saol Therapeutics Inc, Centrexion Therapeutics, Taiwan Liposome Company, MiMedx, Ampio Pharmaceuticals, ReNu, Medipost, and others |
| Key Knee Osteoarthritis Therapies | PTP-001, StroMel, GNSC-001, IMM01-STEM, RHH646, Lorecivivint, Resiniferatoxin, DFV890, Celltex- AdMSCs, Micronized DHACM, X0002, Retatrutide, JointStem, Semaglutide, FX201, RTX-GRT7039, TTAX03, TG-C, SL-1002, CNTX-4975, TLC599, Amniofix, Ampion, Organogenesis, Cartistem, and others |
Scope of the Knee Osteoarthritis Market Report
- Therapeutic Assessment: Knee Osteoarthritis current marketed and emerging therapies
- Knee Osteoarthritis Market Dynamics: Attribute Analysis of Emerging Knee Osteoarthritis Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Knee Osteoarthritis Market Access and Reimbursement
Discover more about knee osteoarthritis drugs in development @ Knee Osteoarthritis Clinical Trials
Table of Contents
| 1. | Knee Osteoarthritis Market Key Insights |
| 2. | Knee Osteoarthritis Market Report Introduction |
| 3. | Knee Osteoarthritis Market Overview at a Glance |
| 4. | Knee Osteoarthritis Market Executive Summary |
| 5. | Disease Background and Overview |
| 6. | Knee Osteoarthritis Treatment and Management |
| 7. | Knee Osteoarthritis Epidemiology and Patient Population |
| 8. | Patient Journey |
| 9. | Knee Osteoarthritis Marketed Drugs |
| 10. | Knee Osteoarthritis Emerging Drugs |
| 11. | Seven Major Knee Osteoarthritis Market Analysis |
| 12. | Knee Osteoarthritis Market Outlook |
| 13. | Potential of Current and Emerging Therapies |
| 14. | KOL Views |
| 15. | Unmet Needs |
| 16. | SWOT Analysis |
| 17. | Appendix |
| 18. | DelveInsight Capabilities |
| 19. | Disclaimer |
| 20. | About DelveInsight |
Related Reports
Knee Osteoarthritis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key knee osteoarthritis companies, including Bone Therapeutics, Moebius Medical, UnicoCell Biomed CO. LTD, Gwo Xi Stem Cell Applied Technology, Bioventus LLC, CAR-T (Shanghai) Biotechnology, Novartis, Personalized Stem Cells, Centrexion Therapeutics, Akan Biosciences, Purdue Pharma, Anika Therapeutics, Peptinov SAS, Flexion Therapeutics, Centrexion Therapeutics, Taiwan Liposome Company, Techfields Pharma, AstraZeneca, Ampio Pharmaceuticals, BioIntegrate, Sorrento Therapeutics, Swiss Medica XXI Century S.A., OrthoTrophix, Amzell, Eupraxia Pharmaceuticals, Meluha Life Sciences, Vivex Biomedical, Orient Europharma Co., Ltd., Paradigm Biopharmaceuticals, Abbvie, Galapagos NV, Regeneron Pharmaceuticals, Xalud Therapeutics, Yooyoung Pharmaceutical, Eupraxia Pharmaceuticals, Celltex Therapeutics Corporation, Eli Lilly and Company, Mestex AG, Mitsubishi Tanabe Pharma Corporation, Propella Therapeutics, Biosplice Therapeutics, Jiangsu XinChen-Techfields Pharma Co., LTD., Teva Pharmaceutical Industries, Pfizer, Grünenthal GmbH, PMG Pharm Co., Ltd, Nordic Bioscience A/S, BUZZZ Pharmaceuticals Limited, Antibe Therapeutics, Saol Therapeutics Inc, LG Chem, among others.
Osteoarthritis Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key osteoarthritis companies including Biosplice Therapeutics, Gilead Sciences, Flexion Therapeutics, GlaxoSmithKline, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Corporation, Bioventus, Medipost, Moebius Medical, ReqMed, TissueTech, Novartis, AstraZeneca, Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Taiwan Liposomal Company, K-STEMCELL, Stempeutics, Levolta Pharmaceuticals, among others.
Osteoarthritis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key osteoarthritis companies, including Biosplice Therapeutics, Gilead Sciences, Flexion Therapeutics, GlaxoSmithKline, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Corporation, Bioventus, Medipost, Moebius Medical, ReqMed, TissueTech, Novartis, AstraZeneca, Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Taiwan Liposomal Company, K-STEMCELL, Stempeutics, Levolta Pharmaceuticals, among others.
Erosive Hand Osteoarthritis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key erosive hand osteoarthritis companies, including Paradigm Biopharmaceuticals, Abbvie, Galapagos NV, Regeneron Pharmaceuticals, Xalud Therapeutics, Yooyoung Pharmaceutical, among others.
Erosive Hand Osteoarthritis Market
Erosive Hand Osteoarthritis Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key erosive hand osteoarthritis companies including Paradigm Biopharmaceuticals, Abbvie, Galapagos NV, Regeneron Pharmaceuticals, Xalud Therapeutics, Yooyoung Pharmaceutical, among others.
Other Trending Reports
Ophthalmic Imaging Equipment Market | Pertussis Market | Recurrent Blood Clots Market | Respiratory Syncytial Virus Market | Systemic Juvenile Idiopathic Arthritis Market | Urethral Stricture Treatment Devices Market | Uterine Serous Carcinoma Market | Zollinger-Ellison Syndrome Market | Acanthamoeba Keratitis Market | Acquired Hemophilia A Pipeline | Acute Pain Market | Age-Related Hearing Loss Medical Device Market | Angio Suites Market | Balloon Catheters Market | Bartonellosis Market | Candidemia Market | Chronic Hand Eczema Market | Chronic Refractory Gout Market | Encephalomyelitis Market | Eosinophilic Gastroenteritis Market | Follicular Lymphoma Market | Head And Neck Squamous Cell Carcinoma Market | Heart Sounds Sensors Market | Heavy Metal Poisoning Market | Hyperinsulinemic Hypoglycemia Market | Hypoplastic Left Heart Syndrome Hlhs Market | Infectious Arthritis/Septic Arthritis Market | Microvascular Angina Market | Mucinoses Market | Necrotizing Enterocolitis Market | Neurofibromatosis 2 Market | Osteochondrodysplasia Market | Plasmacytoma Market | Post-Cardiac Arrest Syndrome Pcas Market | Progressive Familial Intrahepatic Cholestasis Market | Progressive Supranuclear Palsy Market | Pyruvate Kinase Deficiency Market | Recurrent Pericarditis Market | Relapsing Refractory Multiple Myeloma Market | Renal Fanconi Syndrome Market | Wiskott-Aldrich Syndrome Market | Advanced Cancer Pain Management Market | Agoraphobia Market | Alagille Syndrome Market | Atypical Hemolytic Uremic Syndrome Ahus Market | Clinically Isolated Syndrome CIS Market | Conductive Hearing Loss Market | Condyloma Market | Familial Lipoprotein Lipase Deficiency Market | Fucosidosis Market | Glaucoma Drainage Devices Market | H3N2 Infection Market | Hepatitis D Market | Hypopituitarism Market | Hypothalamic Obesity Market | Major Depressive Disorder Market | Muscle Spasticity Market | Musculoskeletal Pain Market Insights | Neurofibromatosis Type 2 Market | Neuronal Ceroid-Lipofuscinoses Market | Paranasal Sinus Cancer Market | Portal Hypertension Market | Propionic Acidemia Market | Systemic Inflammatory Response Syndrome Market Insights | Walking Impairment In Multiple Sclerosis Market | Wet-Age-Related Macular Degeneration Market
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
